Search

Displaying results 3171 - 3180 of 10000 in total
  1. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]

  2. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

  3. Drug

    Dapsone

    go.drugbank.com/drugs/DB00250
    ApprovedInvestigational

    It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) … Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms.

  4. Drug

    Pimagedine

    go.drugbank.com/drugs/DB05383
    Investigational

    It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. … It is beneficial in treating patients with diabetic nephropathy.

  5. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...

  6. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    The defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.

  7. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … Tretten is manufactured as an intracellular, soluble protein in yeast (Saccharomyces cerevisiae) production strain containing the episomal expression vector, pD16.

  8. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.

  9. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). … The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling.

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. … Droloxifene may have an effect on bone and breast tissue because it induces apoptosis.

    Categories: Compounds used in a research, industrial, or household setting